Daniel Farke: 'Leeds deserved to beat Man Utd'

United took the lead through Bryan Mbeumo in the first half, but Dominic Calvert-Lewin equalised after the break to earn Leeds a point.

The statistics supported Farke's argument, with Leeds recording a higher expected goals figure of 1.44, five shots on target and 21 touches in the opposition penalty area.

"We are slightly disappointed it is just a point," Farke told Sky Sports. "Overall, I felt it was not necessary to be losing at half-time, but it is still Manchester United."

Farke was pleased with Leeds' response after the break but felt they could have done more to turn their superiority into victory.

"Second half, we got the equaliser. We should have kept up the dominance, too many strikes went over the crossbar, but it was overall a solid performance," he said.

"We should have won the game, but we move on."

The Leeds manager also welcomed the fact that his team were considered favourites by some observers going into the contest, believing it reflected their progress in recent weeks.

"We took it as a compliment that we have done many things right over the last month if we were seen as favourites against Manchester United, but we have earned this," Farke said. "We wanted to prove the comments right."

Despite controlling much of the contest, Leeds lacked the finishing quality needed to claim the victory.

"We were the dominant side but we couldn't capitalise as we lacked quality in and around the box," Farke admitted.

The draw nevertheless reinforced his belief that Leeds are moving in the right direction, with the club reportedly preparing to offer him a new contract following their encouraging start to the season.

"It says a lot about how much respect we have earned," he said. "Overall, this is where we are at the moment, and overall, it is a good place to be."

Farke knows his side must become more clinical if they are to turn strong performances into victories in the Premier League.

"It is still difficult in this league to win points. You have to be clinical and be very, very effective, but we have to keep going," he added.